Impact Factor
3.07
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.71
330 total citations
h5-index
22
h5 depth signal
Cited share
56.0%
70 of 125
Total citations
330
Citation footprint
Metric signal
1.93
External metric anchor
Self-citation
1.8%
6 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
246
United Kingdom
220
China
95
Slovenia
83
Iran
37
Citing Fields of Research
Stem Cell Biology
572
Musculoskeletal Disorders
109
Medical Ethics
78
Wounds & Ulcers
53
Nervous System Disorders
37
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,894
Articles tracked across the journal lifetime
Indexed publication set
125
70 cited publications
Last 12 months
60
5.0 publications/month
Open access share
20.0%
12 OA publications in the last year
Leading citing country
United States
246 citing publications
Leading citing field
Stem Cell Biology
572 citing publications
Latest tracked publication
11 September 2026
10 recent records available
Coverage & Indexing History
v1n1, Jan. 2006-
v1n1, Jan. 2006-
Active Coverage
Research Focus & Classification
Indexed Subjects
Stem Cell Biology
Broad Categories
Biotechnology
Stem Cell Biology
Musculoskeletal Disorders
Nervous System Disorders
Nanofibers, Scaffolds & Fabrication
MeSH Descriptors
Regenerative Medicine
Stem Cells
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1080/17460751.2026.2731198
Open DOI
Industry updates in advanced therapy medicinal products and regenerative medicine – August 2026
1. 1.1. Text-based logo graphic with CREATE Medicines and WestGene Biopharma side by side. CREATE Medicines (MA, USA; https://createmedicines.com), a clinical-stage biotechnology company developing...
02
DOI 10.1080/17460751.2026.2741431
Open DOI
From oncogenesis to approval: the lentiviral gene therapy revolution in Wiskott–Aldrich syndrome
03
DOI 10.1080/17460751.2026.2741432
Open DOI
Extracorporeal shockwave therapy in musculoskeletal conditions: a narrative review
04
DOI 10.1080/17460751.2026.2730229
Open DOI
Clinical manufacturing of adipose-derived stem cells for therapeutic use: current technologies, quality systems and production challenges
1. This systematic review aims to identify, describe and critically appraise current clinical manufacturing technologies, quality systems, economic frameworks and regulatory pathways for adipose-de...
05
DOI 10.1080/17460751.2026.2726833
Open DOI
Early economic evaluation of tissue engineered vascular access grafts for hemodialysis
1. Kidney disease is projected to become the fifth leading cause of life years lost in 2040 worldwide [1]. Over 2.5 million people globally suffer from end stage kidney disease (ESKD) leading to he...
06
DOI 10.1080/17460751.2026.2730232
Open DOI
From targeted drug delivery to tissue regeneration: the evolving role of nanoparticle therapies in liver disease
1. Chronic liver diseases (CLD), a group of disorders involving the gradual deterioration of liver tissue and function over time, are rapidly emerging as major causes of morbidity and mortality wor...
07
DOI 10.1080/17460751.2026.2719466
Open DOI
Industry updates in advanced therapy medicinal products and regenerative medicine – July 2026
1. 1.1. Apertura Gene Therapy & NIH Tech Transfer logo.Apertura Gene Therapy (NY, USA; https://aperturagtx.com), a biotechnology company developing engineered adeno-associated virus (AAV) vectors, ...
08
DOI 10.1080/17460751.2026.2706785
Open DOI
Industry updates in advanced therapy medicinal products and regenerative medicine – June 2026
1. 1.1. Text-based logo banner with two company logos: VectorBuilder and MaxCyte.VectorBuilder (IL, USA; https://en.vectorbuilder.com), a gene-delivery technology and Contract Development and Manuf...
09
DOI 10.1080/17460751.2026.2723032
Open DOI
Combined umbilical cord-derived mesenchymal stem cell exosome and cell therapy in heart failure with reduced ejection fraction
1. The inability of cardiomyocytes to regenerate after scar tissue formation caused by ischemic or non-ischemic injury is a well-recognized phenomenon [1]. Despite significant advances in the manag...
10
DOI 10.1080/17460751.2026.2719471
Open DOI
Bovine umbilical cord tissue‑derived MSCs and its conditioned medium promote the healing of excisional wound in rats
1. Wound healing has always been a crucial issue to solve due to the presence of numerous cells and molecules working in concert. The factors influencing this process are the type of injury, underl...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.